Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide in Myelofibrosis
NCT00669578Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- May 2008
- Primary completion
- Jul 2010
- Countries
- 1
01
Overview
Phase 2, open-label trial of pomalidomide in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by Mayo Clinic. Primary endpoint: Maximum Tolerated Dose at 28 days. Started May 2008; status: completed.
02
Drugs
pomalidomide
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NCT00669578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00669578.